Treatment

Treatment of Fabry

Naomi.JPG

Replagal® and Fabrazyme® are Enzyme Replacement Therapies for Fabry disease both approved in the European Union. Replagal was developed and is produced by Shire Human Genetic Therapies. Fabrazyme was developed and is produced by Genzyme. For additional information please visit www.shire.com and www.fabrazyme.com

You can also visit our  section for information on clinical trials